CAR therapies
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.
Janssen Seeking European Approval for Carvykti as Earlier Refractory Multiple Myeloma Treatment
The firm submitted data from CARTITUDE-4, which showed the CAR T-cell therapy improved patients' progression-free survival compared to standard-of-care regimens.
Phio Pharmaceuticals, AgonOx Start Phase I Trial of T-Cell Immunotherapy Combination
The firms will evaluate Phio's self-delivering RNAi compound PH-762 plus AgonOx's autologous tumor-infiltrating lymphocyte therapy in a variety of cancers.
FDA, Industry Taking Steps to Streamline Cell Therapy Regulation, Though Uncertainty Remains
Premium
At two recent meetings, representatives from regulatory agencies, industry, and academia discussed ways to foster efficient, more predictable cell therapy regulation.
Nexcella CAR T-Cell Therapy Amyloidosis Trial Yields Promising Safety, Efficacy Data
At ASGCT's annual meeting, researchers shared data suggesting that the autologous cell therapy could benefit patients with the rare, multiple myeloma-associated disease.